Posted 8th March 2019 by Joshua Broomfield
The cascade of new discoveries relating health and disease to our gut microbiome has spurred the notion that we now find ourselves in the middle of a “microbiome revolution”. Just to mention some recent examples, mechanisms have been demonstrated for gut bacteria contributing to Parkinson’s disease, determining response to immune checkpoint inhibitor cancer therapy, and even autistic behavior when fecal material from autistic children was transplanted into mice.
Posted 13th February 2019 by Joshua Broomfield
I was a scientist at Los Alamos National Lab in the US when I identified a science-based personalized diet that completely cured my early onset arthritis. I realized that the gut microbiome would play a central role in personalized nutrition and redirected all my science projects towards it. We desperately needed better technology for analysing the gut microbiome and metatranscriptomics offers the best value. It is better than 16S or metagenomic sequencing in two important aspects:
Posted 25th January 2019 by Joshua Broomfield
In December 2014, a major flood in north-eastern Peninsular Malaysia affected more than 200,000 people leaving them homeless, with no clean water, and sick with diseases including dengue fever, typhoid, leptospirosis and acute gastroenteritis (approximately 30% of flood-affected population). After 6 months, many were still affected by illness including persistent abdominal pain and diarrhoea. We investigated two of the worst flood-affected communities (Figure A) on their microbiota profile and if a probiotic can help. Following are 5 points I have learned from this invaluable experience:
Posted 27th December 2017 by Laura Berry
Defined health outcomes are increasingly being linked to prebiotic ingredients and supplements. For example, mounting evidence recently led the FDA to issue a qualified health claim regarding the ability of digestion resistant starch to reduce the risk of type 2 diabetes. With the direct annual cost of diabetes recently estimated to be $825B (1), the potential application of prebiotics to reduce disease risk is appealing from both health care and business investment perspectives.